Literature DB >> 9222976

The mitochondrial A3243G mutation presenting as severe cardiomyopathy.

L Vilarinho1, F M Santorelli, M J Rosas, C Tavares, M Melo-Pires, S DiMauro.   

Abstract

A 6 year old Portuguese boy with dilated cardiomyopathy had abundant ragged red fibres in muscle (20% of total) and severe lactic acidosis. Molecular genetic analysis showed the A to G transition in the mitochondrial transfer RNALeu(UUR) gene at nt 3243 ("MELAS mutation"), which accounted for 88% and 68% of the total mtDNA in his muscle and blood, respectively. Molecular studies in blood from 16 maternal relatives identified lower percentages of the mutation only in the oligo-symptomatic mother and brother. This case reinforces the notion that cardiomyopathy can be the presenting and predominant clinical expression of the A3243G mutation.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9222976      PMCID: PMC1051008          DOI: 10.1136/jmg.34.7.607

Source DB:  PubMed          Journal:  J Med Genet        ISSN: 0022-2593            Impact factor:   6.318


  16 in total

1.  Cytochrome c oxidase deficiency in Leigh syndrome.

Authors:  S DiMauro; S Servidei; M Zeviani; M DiRocco; D C DeVivo; S DiDonato; G Uziel; K Berry; G Hoganson; S D Johnsen
Journal:  Ann Neurol       Date:  1987-10       Impact factor: 10.422

2.  Pearson syndrome and mitochondrial encephalomyopathy in a patient with a deletion of mtDNA.

Authors:  M A McShane; S R Hammans; M Sweeney; I J Holt; T J Beattie; E M Brett; A E Harding
Journal:  Am J Hum Genet       Date:  1991-01       Impact factor: 11.025

3.  Mitochondrial mutation in fatal infantile cardiomyopathy.

Authors:  M Tanaka; H Ino; K Ohno; K Hattori; W Sato; T Ozawa; T Tanaka; S Itoyama
Journal:  Lancet       Date:  1990-12-08       Impact factor: 79.321

4.  Cardiac involvement in mitochondrial diseases, and vice versa.

Authors:  R S Williams
Journal:  Circulation       Date:  1995-02-15       Impact factor: 29.690

5.  MELAS point mutation with unusual clinical presentation.

Authors:  A L Shanske; S Shanske; G Silvestri; K Tanji; D Wertheim; S Lipper
Journal:  Neuromuscul Disord       Date:  1993-05       Impact factor: 4.296

6.  Atypical clinical presentations associated with the MELAS mutation at position 3243 of human mitochondrial DNA.

Authors:  C T Moraes; F Ciacci; G Silvestri; S Shanske; M Sciacco; M Hirano; E A Schon; E Bonilla; S DiMauro
Journal:  Neuromuscul Disord       Date:  1993-01       Impact factor: 4.296

7.  Mutation in mitochondrial tRNA(Leu)(UUR) gene in a large pedigree with maternally transmitted type II diabetes mellitus and deafness.

Authors:  J M van den Ouweland; H H Lemkes; W Ruitenbeek; L A Sandkuijl; M F de Vijlder; P A Struyvenberg; J J van de Kamp; J A Maassen
Journal:  Nat Genet       Date:  1992-08       Impact factor: 38.330

Review 8.  Mitochondrial myopathy, encephalopathy, lactic acidosis, and strokelike episodes (MELAS): current concepts.

Authors:  M Hirano; S G Pavlakis
Journal:  J Child Neurol       Date:  1994-01       Impact factor: 1.987

9.  Cardiac involvement in mitochondrial diseases. A study on 17 patients with documented mitochondrial DNA defects.

Authors:  R Anan; M Nakagawa; M Miyata; I Higuchi; S Nakao; M Suehara; M Osame; H Tanaka
Journal:  Circulation       Date:  1995-02-15       Impact factor: 29.690

10.  The mitochondrial tRNA(Leu(UUR)) mutation in mitochondrial encephalomyopathy, lactic acidosis, and strokelike episodes (MELAS): genetic, biochemical, and morphological correlations in skeletal muscle.

Authors:  C T Moraes; E Ricci; E Bonilla; S DiMauro; E A Schon
Journal:  Am J Hum Genet       Date:  1992-05       Impact factor: 11.025

View more
  12 in total

Review 1.  Mitochondrial DNA analysis: polymorphisms and pathogenicity.

Authors:  P F Chinnery; N Howell; R M Andrews; D M Turnbull
Journal:  J Med Genet       Date:  1999-07       Impact factor: 6.318

Review 2.  Functional, structural, and genetic mitochondrial abnormalities in myocardial diseases.

Authors:  A Brega; J Narula; E Arbustini
Journal:  J Nucl Cardiol       Date:  2001 Jan-Feb       Impact factor: 5.952

Review 3.  Clinical mitochondrial genetics.

Authors:  P F Chinnery; N Howell; R M Andrews; D M Turnbull
Journal:  J Med Genet       Date:  1999-06       Impact factor: 6.318

4.  Rapid and sensitive real-time polymerase chain reaction method for detection and quantification of 3243A>G mitochondrial point mutation.

Authors:  Rinki Singh; Sian Ellard; Andrew Hattersley; Lorna W Harries
Journal:  J Mol Diagn       Date:  2006-05       Impact factor: 5.568

Review 5.  tRNA Metabolism and Neurodevelopmental Disorders.

Authors:  Ashleigh E Schaffer; Otis Pinkard; Jeffery M Coller
Journal:  Annu Rev Genomics Hum Genet       Date:  2019-05-13       Impact factor: 8.929

6.  Pulmonary artery hypertension in a child with MELAS due to a point mutation of the mitochondrial tRNA((Leu)) gene (m.3243A>G).

Authors:  D M Sproule; J Dyme; J Coku; D de Vinck; E Rosenzweig; W K Chung; D C De Vivo
Journal:  J Inherit Metab Dis       Date:  2008-01-07       Impact factor: 4.982

7.  Selection against pathogenic mtDNA mutations in a stem cell population leads to the loss of the 3243A-->G mutation in blood.

Authors:  Harsha Karur Rajasimha; Patrick F Chinnery; David C Samuels
Journal:  Am J Hum Genet       Date:  2008-02       Impact factor: 11.025

8.  Mitochondrial cardiomyopathies: how to identify candidate pathogenic mutations by mitochondrial DNA sequencing, MITOMASTER and phylogeny.

Authors:  Michael V Zaragoza; Martin C Brandon; Marta Diegoli; Eloisa Arbustini; Douglas C Wallace
Journal:  Eur J Hum Genet       Date:  2010-10-27       Impact factor: 4.246

Review 9.  Cardiological manifestations of mitochondrial respiratory chain disorders.

Authors:  A Berardo; O Musumeci; A Toscano
Journal:  Acta Myol       Date:  2011-06

10.  Cardiac abnormalities in patients with mitochondrial DNA mutation 3243A>G.

Authors:  Kirsi Majamaa-Voltti; Keijo Peuhkurinen; Marja-Leena Kortelainen; Ilmo E Hassinen; Kari Majamaa
Journal:  BMC Cardiovasc Disord       Date:  2002-08-01       Impact factor: 2.298

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.